Author of

• 32842

  +

  GS04 - Patient Selection for Local Therapies in the Era of Immunotherapy (ID 10)

  • Event: NACLC 2019
  • Type: Invited Speaker Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/11/2019, 10:15 - 11:15, Rouge (Lobby Level)

  • 33208

    +

    GS04.05 - Recurrence after SBRT (ID 168)

    10:15 - 11:15  |  Presenting Author(s): Mara B. Antonoff
    • Abstract
    • Slides

    Abstract not provided

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

• 32849

  +

  OA02 - Screening and IO Toxicity (ID 2)

  • Event: NACLC 2019
  • Type: Oral Abstract Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/12/2019, 09:45 - 11:15, Imperial Ballroom (B2 Level)

  • 33317

    +

    OA02.09 - Multi-Planar Lung Cancer Measurements Provide Improved Accuracy in Clinical Staging (ID 111)

    09:45 - 11:15  |  Author(s): Mara B. Antonoff, Mara B. Antonoff
    • Abstract
    • Slides

    Background:
    Despite the wealth of information available via routine diagnostic computed tomography (CT), tumors are conventionally measured and reported in the axial dimension only. The extent to which this practice may underestimate tumor burden and impair accurate clinical staging is unknown. We sought to evaluate the impact of adding sagittal and coronal measurements to patient imaging review, as well as its role in determining candidates for potential neoadjuvant treatment in advance of surgical resection.
    
    
    Method:
    Consecutive patients were identified who underwent upfront surgery from 2010-2015 for clinical T2N0-1 non-small cell lung cancer (AJCC 7th Edition) at a single institution. Patients without available pre-operative CT, with pre-operative CT of poor quality (slice thickness >5mm), and patients who had multifocal disease or associated atelectasis precluding accurate tumor measurement were excluded. Imaging was reviewed by thoracic radiologists and longest tumor diameter in axial, sagittal, and coronal planes were reported.
    
    
    Results:
    152 patients were identified for detailed imaging review, including 106 (70%) who were initially reported as T2a and 46 (30%) T2b based upon axial images. Review of reformats revealed T stages ranging from T1b-T3 in the coronal plane, and T1a-T3 in the sagittal plane (Table). Axial-coronal and axial-sagittal T stage concordance were 76% (115/152) and 75% (114/152), respectively. Coronal-sagittal concordance was 70% (106/152). Importantly, 5% (8/152) were upstaged to T3 based upon three-dimensional measurements, suggesting a potential missed opportunity for induction chemotherapy. Spearman’s correlation coefficient demonstrated the highest agreement between pathologic tumor size and axial diameter (?=0.70), as compared to coronal (?=0.68) and sagittal (?=0.64) measurements.
    
    
    Conclusion:
    A modest but important proportion of patients are eligible for chemotherapy when three-dimensional tumor measurements are employed. Because prior investigations have demonstrated improved compliance with regards to completion of chemotherapy in the neoadjuvant (versus adjuvant) setting, routine measurement of tumors in three dimensions should be considered.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.